Safety and Efficacy of Ranibizumab for Diabetic Macular Edema

Summary

The primary objective of the study is to assess the ocular and systemic adverse events of ranibizumab (Lucentis)for DME (diabetic macular edema) following previous treatment with intravitreal bevacizumab (Avastin).

Timeline

Start

2014-06-24

Primary completion

2016-05-26

Completion

2016-05-26

Drugs

Indications